Therapeutics

The first scientific presentation of previously announced data from Cohort 1 of an ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg twice daily) in IPF, confirms positive trends in seven of the eight biomarkers evaluated,…

In one of the recent deals, Gary Charles Robb, Chief Business Officer at... Corcept Treatments (NASDAQ:), sold shares of the company's common stock for a total value of approximately $509,080. The sale, dated October 1, 2024,…

Oppenheimer maintained a positive outlook on Jasper Therapeutics (NASDAQ: JSPR), reiterating an Outperform rating with a firm price target of $80.00. The company's position comes after evaluating long-term results from a phase 2 study of…

According to a new filing with the U.S. Securities and Exchange Commission, Emily Pimblett, chief accounting officer of Eliem Therapeutics, Inc. (NASDAQ:ELYM), recently sold a portion of her company’s stock. The transactions, which took…

BOSTON--(BUSINESS WIRE)--Asteria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immune diseases, today announced that it will present preliminary data for…

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics (Nasdaq: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for the treatment of serious and rare diseases, today announced the…

Biora Therapeutics has reported significant advancements in its BT-600 program and BioJet platform during its recent earnings call. The company announced successful Phase I clinical trial results for its BT-600 program, utilizing the…

On Wednesday, Scotiabank revised its outlook on Sage Therapeutics (NASDAQ:SAGE), lowering its price target to $17 from $19 previously while maintaining a sector outperform rating on the stock. The decision comes after the company's recent…

In a recent move, Kentara Therapeutics, a San Diego, California-based pharmaceutical company, has officially withdrawn its designation of two types of preferred stock. The company, listed on the Nasdaq Capital Market under the symbol KTRA,…

This section is Partnership Content ProvidedThe content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe…